Atea Pharmaceuticals (NASDAQ:AVIR) Announces Quarterly Earnings Results

Atea Pharmaceuticals (NASDAQ:AVIR) released its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05), Zacks reports.

Atea Pharmaceuticals Stock Down 0.3 %

NASDAQ:AVIR traded down $0.01 during midday trading on Thursday, hitting $3.00. The stock had a trading volume of 304,423 shares, compared to its average volume of 280,587. The company has a market capitalization of $253.39 million, a price-to-earnings ratio of -1.45 and a beta of 0.18. The stock has a 50-day moving average of $3.17 and a 200 day moving average of $3.35. Atea Pharmaceuticals has a one year low of $2.75 and a one year high of $4.18.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of Atea Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total value of $1,024,877.10. Following the transaction, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. The trade was a 44.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 17.80% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.